Previous 10 | Next 10 |
Reports 1Q product sales of $29.0M, up 42% year-over-year Encouraging interim update from ANCHOR study of KUR-502 presented at ASTCT with 60% overall response rate (ORR) and 6-month complete response (CR) rate of 29% in the NHL cohort Abstract for KUR-501 in GINAKIT2 stu...
Data presented by investigators from the Texas Children’s Cancer Center’s Center for Advanced Innate Cell Therapy and Baylor College of Medicine Data demonstrate expansion of CAR-NKT cells post-transfer in all patients, and objective responses in patients with rela...
BUFFALO, N.Y., April 29, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provid...
Athenex (NASDAQ:ATNX) reported data from a phase 1 trial of KUR-502 (Allogeneic CD19 CAR-NKT Cells) to treat patients with non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL). The company said NKT cells were isolated from the leukapheresis product of one HLA-unmatched ...
Interim analysis provides response data from 7 evaluable patients including two additional patients, one with non-Hodgkin lymphoma (NHL) and one with acute lymphoblastic leukemia (ALL) Six-month CR rate of 29%, including 1 ongoing CR at 34 weeks in heavily pretreated patients ...
Athenex Inc. (NASDAQ:ATNX) traded at a new 52-week high today of $23.00. Approximately 91.4 million shares have changed hands today, as compared to an average 30-day volume of 900,000 shares. In the past 52 weeks, Athenex Inc. share prices are bracketed by a low of $0.73 and a high of $2...
Athenex, Inc. (ATNX) Q4 2021 Earnings Conference Call March 16, 2022, 4:30 PM ET Company Participants Johnson Lau – Chief Executive Officer Caileigh Dougherty – Investor Relations Dan Lang – President, Athenex Cell Therapy Kurt Gunter – Chief Medical Officer, Cell ...
Athenex press release (NASDAQ:ATNX): Q4 GAAP EPS of -$0.95 misses by $0.62. Revenue of $24.94M (+14.4% Y/Y) misses by $5.88M. For further details see: Athenex GAAP EPS of -$0.95 misses by $0.62, revenue of $24.94M misses by $5.88M
Buffalo, New York-based biotech Athenex (NASDAQ:ATNX) said on Wednesday that the company is implementing cost-cutting measures and monetization of non-core assets to extend the cash runway this year. Following the announcement, Athenex (ATNX) shares lost ~7% in the post-market. With...
Announces Strategic Pivot to Focus on Cell Therapy Programs Receives FDA Clearance for IND to Expand CD19 CAR-NKT ANCHOR to a Multi-center Study Implementing Significant Cost Reduction Plan Targeting >50% Reduction in Operating Expenses Plans to Extend Cash Ru...
News, Short Squeeze, Breakout and More Instantly...
Athenex Inc. Company Name:
ATNX Stock Symbol:
NASDAQ Market:
To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (...
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO PR Newswire SAN FRANCISCO , May 1, 2023 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and At...
Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $1...